PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
PRTC Puretech Health
- 18.950
- 0.0000.00%
Close Feb 14 16:00 ET
453.70MMarket Cap-6.32P/E (TTM)
19.510High18.060Low4.15KVolume19.510Open18.950Pre Close78.78KTurnover0.03%Turnover RatioLossP/E (Static)23.94MShares34.00052wk High1.44P/B300.54MFloat Cap17.00052wk Low--Dividend TTM15.86MShs Float65.900Historical High--Div YieldTTM7.65%Amplitude17.000Historical Low18.986Avg Price1Lot Size
Trending Stocks
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?
Puretech Health Stock Forum
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
The FDA Has Granted Fast Track Designation To PureTech Health's LYT-200 For Acute Myeloid Leukemia
Benzinga· 04:081min
Puretech Health(PRTC.US)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatmentLYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers
No comment yet